Table 1 Patient characteristics, clinical presentation, and treatment patterns by immune status cohort.

From: Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

 

Total

n = 344 (%)

HIV-PBL

n = 164 (%)

PTLD-PBL

n = 19 (%)

OIS-PBL

n = 36 (%)

IC-PBL

n = 125 (%)

p-value*

Age at diagnosis (y)

Median (Range)

< 60

≥ 60

53 (19-91)

212 (62)

132 (38)

46 (19-76)

150 (91)

14 (9)

55 (23-75)

11 (58)

8 (42)

67 (21-88)

10 (28)

26 (72)

68 (20-91)

41 (33)

84 (67)

<0.001

Sex

Male

Female

270 (78)

74 (22)

141 (86)

23 (14)

13 (68)

6 (32)

22 (61)

14 (39)

94 (75)

31 (25)

0.003

Year of diagnosis

2005–2009

2010–2014

2015–2019

2020–2022

29 (8)

75 (22)

158 (46)

82 (24)

23 (14)

40 (24)

75 (46)

26 (16)

0 (0)

6 (32)

7 (36)

6 (32)

2 (6)

5 (14)

15 (42)

14 (38)

4 (3)

24 (19)

61 (49)

36 (29)

0.003

Race

White

Black/African American

Other

Unknown

230 (67)

59 (17)

34 (10)

21 (6)

90 (55)

44 (27)

23 (14)

7 (4)

16 (85)

1 (5)

1 (5)

1 (5)

28 (77)

5 (14)

1 (3)

2 (6)

96 (77)

9 (7)

9 (7)

11 (9)

<0.001

Ethnicity

Hispanic/Latino

Non-Hispanic/Latino

Other/Unknown

114 (33)

206 (60)

24 (7)

62 (38)

94 (57)

8 (5)

2 (11)

16 (84)

1 (5)

13 (36)

19 (53)

4 (11)

37 (30)

77 (62)

11 (8)

0.143

ECOG Performance Status

≤ 1

2+

Unknown

227 (66)

74 (22)

43 (12)

104 (64)

35 (21)

25 (15)

13 (68)

2 (11)

4 (21)

25 (69)

9 (25)

2 (6)

85 (68)

28 (22)

12 (10)

0.773

Ann Arbor Stage

I

II

III

IV

Unknown

52 (15)

33 (10)

22 (6)

227 (66)

10 (3)

15 (9)

18 (11)

13 (8)

114 (70)

4 (2)

4 (21)

0 (0)

0 (0)

13 (68)

2 (11)

6 (16)

2 (6)

4 (11)

24 (67)

0 (0)

27 (22)

13 (10)

5 (4)

76 (61)

4 (3)

0.071

Nodal Disease

Yes

No

Unknown

215 (63)

112 (33)

17 (4)

112 (68)

44 (27)

8 (5)

8 (42)

11 (58)

0 (0)

23 (64)

13 (36)

0 (0)

72 (58)

44 (35)

9 (7)

0.046

Extranodal Disease

Yes

No

Unknown

316 (92)

24 (7)

4 (1)

149 (91)

12 (7)

3 (2)

17 (89)

2 (11)

0 (0)

33 (92)

3 (8)

0 (0)

117 (94)

7 (5)

1 (1)

0.837

LDH Elevation

>1x ULN

Not Elevated

Unknown

177 (51)

124 (36)

43 (13)

100 (61)

48 (29)

16 (10)

7 (37)

7 (37)

5 (26)

21 (58)

13 (36)

2 (6)

49 (39)

56 (45)

20 (16)

0.009

IPI at diagnosis, mean (SD)*

2.51 (1.32)

2.50 (1.14)

2.38 (1.39)

2.88 (1.34)

2.42 (1.52)

0.423

MYC Rearrangement

+

−

Unknown

45 (13)

33 (10)

266 (77)

26 (16)

9 (5)

129 (79)

2 (11)

2 (11)

15 (78)

7 (19)

6 (17)

23 (64)

10 (8)

16 (13)

99 (79)

0.045

CNS Involvement

Yes

No

Unknown

11 (3)

329 (96)

4 (1)

6 (4)

155 (95)

3 (1)

0 (0)

19 (100)

0 (0)

0 (0)

36 (100)

0 (0)

5 (4)

119 (95)

1 (1)

0.529

Head/Neck Involvement

Yes

No

Unknown

94 (27)

246 (72)

4 (1)

53 (32)

108 (66)

3 (2)

2 (11)

17 (89)

0 (0)

3 (8)

33 (92)

0 (0)

36 (29)

88 (70)

1 (1)

0.008

EBV+ by LMP or EBER

+

−

Unknown

194 (56)

112 (33)

38 (11)

25 (15)

118 (72)

21 (13)

5 (26)

13 (68)

1 (5)

23 (64)

13 (36)

0 (0)

59 (47)

50 (40)

16 (13)

<0.001

Chemo Regimen in 1 L**

CHOP/CHOP-like

EPOCH

Hyper-CVAD or CODOX-M/IVAC

Other

44 (14)

220 (64)

26 (8)

19 (6)

17 (10)

110 (67)

17 (10)

9 (5)

1 (5)

15 (79)

1 (5)

1 (5)

10 (28)

19 (53)

0 (0)

2 (6)

16 (13)

76 (61)

8 (6)

7 (6)

0.073

Additional Agents Used in 1 L

Proteasome Inhibitor

Rituximab

Daratumumab

105 (31)

60 (17)

12 (4)

47 (29)

31 (19)

7 (4)

5 (26)

4 (21)

2 (11)

8 (22)

11 (31)

2 (6)

45 (36)

14 (11)

1 (1)

0.028

CNS PPx in 1 L

IT MTX and/or AraC

HD MTX

None

Unknown

90 (26)

23 (7)

179 (52)

52 (15)

50 (30)

16 (10)

74 (45)

24 (15)

2 (11)

0 (0)

11 (58)

6 (31)

5 (14)

0 (0)

25 (69)

6 (17)

33 (26)

7 (6)

69 (55)

16 (13)

0.024

Consolidative RT in 1 L

Yes

No

Unknown

63 (18)

270 (78)

11 (3)

21 (13)

142 (86)

1 (1)

3 (16)

14 (74)

2 (10)

6 (17)

30 (83)

0 (0)

33 (26)

84 (68)

8 (6)

0.014

Consolidative ASCT in 1 L

Yes

No

Unknown

27 (8)

307 (89)

10 (3)

13 (8)

150 (91)

1 (1)

0 (0)

17 (89)

2 (11)

4 (11)

32 (89)

0 (0)

10 (8)

108 (86)

7 (6)

0.580

  1. SD Standard deviation.
  2. *Bolded p-values are statistically significant. P-values do not account for missing data rows. SD Standard deviation. **More detailed description in Supplementary Table 2.
Back to article page